ARWR
Arrowhead Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website arrowheadpharma.com
- Employees(FY) 525
- ISIN US04280A1007
Performance
+0.2%
1W
+4.65%
1M
-15.98%
3M
-4.95%
6M
-19.05%
YTD
-33.23%
1Y
Profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Investment Analysis Report: ARWR
Overview
In this investment analysis report, we will delve into the financial statements of ARWR, a company operating in the Health Technology sector, specifically in the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating...
Technical Analysis of ARWR 2024-05-10
Overview:
In analyzing the technical indicators for ARWR over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-16 06:27
ARWR: Summer Webinar Series to Highlight Development Pipeline…(Zacks Small Cap Research)
- 2024-05-13 19:08
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025(Investorplace)
- 2024-05-10 13:03
- 2024-05-10 12:26
- 2024-05-10 11:32
- 2024-05-09 16:34
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2(MT Newswires)
- 2024-05-09 16:14
Arrowhead Research: Fiscal Q2 Earnings Snapshot(Associated Press Finance)
- 2024-05-09 16:01
- 2024-05-09 11:54
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024(Investorplace)
- 2024-05-09 04:01
- 2024-05-03 07:26
- 2024-05-02 16:01
- 2024-05-02 04:01
- 2024-04-29 07:30
- 2024-04-28 19:30
- 2024-04-26 07:30
- 2024-04-25 19:30
- 2024-04-24 16:01
- 2024-04-24 07:30
- 2024-04-24 04:01
- 2024-04-23 20:00
ARWR: What does Argus have to say about ARWR?(Argus Research)
- 2024-04-23 19:30
- 2024-04-16 09:00
- 2024-04-16 08:57
- 2024-04-15 21:00
- 2024-04-07 09:00
- 2024-04-06 21:00
- 2024-04-04 01:27
- 2024-04-01 16:30
- 2024-04-01 04:30
Page 1 of 6
previousnext